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Abstract: Novel primaquine (PQ) and halogenaniline asymmetric fumardiamides 4a–f,
potential Michael acceptors, and their reduced analogues succindiamides 5a–f were
prepared by simple three-step reactions: coupling reaction between PQ and mono-ethyl
fumarate (1a) or mono-methyl succinate (1b), hydrolysis of PQ-dicarboxylic acid mono-ester
conjugates 2a,b to corresponding acids 3a,b, and a coupling reaction with halogenanilines.
1-[bis(Dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate
(HATU) was used as a coupling reagent along with Hünig′s base. Compounds 4 and 5 were
evaluated against a panel of bacteria, several Mycobacterium strains, fungi, a set of viruses, and nine
different human tumor cell lines. p-Chlorofumardiamide 4d showed significant activity against
Staphylococcus aureus, Streptococcus pneumoniae and Acinetobacter baumannii, but also against Candida
albicans (minimum inhibitory concentration (MIC) 6.1–12.5 µg/mL). Together with p-fluoro and p-CF3
fumardiamides 4b,f, compound 4d showed activity against Mycobacterium marinum and 4b,f against
M. tuberculosis. In biofilm eradication assay, most of the bacteria, particularly S. aureus, showed
susceptibility to fumardiamides. m-CF3 and m-chloroaniline fumardiamides 4e and 4c showed
significant antiviral activity against reovirus-1, sindbis virus and Punta Toro virus (EC50 = 3.1–5.5
µM), while 4e was active against coxsackie virus B4 (EC50 = 3.1 µM). m-Fluoro derivative 4a exerted
significant cytostatic activity (IC50 = 5.7–31.2 µM). Acute lymphoblastic leukemia cells were highly
susceptible towards m-substituted derivatives 4a,c,e (IC50 = 6.7–8.9 µM). Biological evaluations
revealed that fumardiamides 4 were more active than succindiamides 5 indicating importance of
Michael conjugated system.
Keywords: fumardiamide; primaquine; succindiamide; Michael acceptor; biofilm eradication;
antibacterial screening; antiviral activity; cytostatic activity
1. Introduction
Compounds bearing α,β-unsaturated carbonyl groups are Michael acceptors capable of
conjugate addition, also known as Michael addition. The simplest and the best Michael acceptors
Molecules 2018, 23, 1724; doi:10.3390/molecules23071724 www.mdpi.com/journal/molecules
Molecules 2018, 23, 1724 2 of 18
are α,β-unsaturated carbonyl compounds with exposed unsaturated β-carbon atoms, such as
exomethylene ketones and lactones or vinyl ketones [1]. These fragments are often used in the
design of new anticancer drugs, together with others (6-methylhept-5-ene-1,4-dione, propiolamide,
4-(dimethylamino)but-2-enamide) (Figure 1). They assure the irreversible covalent binding to a cysteine
residue of a specific protein and may modulate selectivity and potency of the drug candidate.
The targeted covalent modification has emerged as a validated approach to drug discovery with
the drug candidate canertinib [2], approved drugs afatinib, neratinib and osimertinib (inhibitors of
human epidermal growth factor receptors) and ibrutinib (Bruton′s tyrosine kinase inhibitor) [3,4].
A comprehensive review published by Jackson et al. gives an overview of biological activity and
applicability of various Michael acceptors [5].
Michael acceptors have been explored in a prodrug strategy for cancer cell-specific targeting.
In the review published by Zhang et al., two doxorubicin prodrugs with maleimide moieties have
been described [6]. The maleimide component is responsible for the binding to human serum albumin.
Once the drug carrier arrives at the targeted cancer tissue, doxorubicin is released from the carrier by
the cleavage of hydrazone or glycosidic bond in the acidic environment of cancer cells. The prodrugs
demonstrate superior anticancer efficacy than the parent drug.
Michael acceptors are present in other classes of drugs. Examples of such drugs are entacapone
(antiparkinsonic) [7], dimethyl fumarate (antipsoriatic; since 2013 used in treatment of multiple
sclerosis) [5], rupintivir (experimental antiviral drug against human rhinoviruses) [8], exemestane
(cytostatic) [9], and ethacrynic acid (diuretic) [10].
α,β-Unsaturated carbonyl group is also a motif found in plant and microbial metabolites and
their semisynthetic/synthetic derivatives. Many of them are used in clinical practice or are still under
the evaluation in clinical trials (vernolepin, helenalin, curcumin, pyrrocidine, fumaric and angelic
acid derivatives), but some are classified as toxins [11]. Vernolepin and helenalin are sesquiterpenes
with exomethylene lactones responsible for irreversible DNA polymerase inhibition. Pyrrocidine
A is a 13-membered macrocyclic alkaloid produced by endophytic fungi, which directly binds to
N-acetyl-L-cysteine methyl ester through the Michael-type addition and exerts both antimicrobial
and cytostatic effect on leukemia HL60 cells [12]. Angelic acid ester ingenol mebutate has been
identified as the most active component of Euphorbia peplus L. latex sap, effective against human
nonmelanoma skin cancer [13] and actinic keratosis [14]. A gel formulation of ingenol mebutate has
been recently approved for the treatment of actinic keratosis [15] and fumaric acid esters are used for
the management of psoriasis [16,17]. Curcumin is a symmetric α,β-unsaturated β-diketone extracted
from Curcuma longa L., a tropical Southeast Asian plant used as a spice and in traditional Indian
medicine [18]. Currently, there are 17 open clinical trials involving curcumin, of which mainly evaluate
the combination of curcumin with other substances used in anticancer therapy [19].
In this paper, we report design and preparation of novel Michael acceptors, fumaric acid diamides
4a–f. We have chosen α,β-unsaturated amides because they are less electrophilic than analogous esters
and better Michael acceptors [1]. Based on our previous findings [20,21], one of the amide bonds
was achieved with a terminal amino group of primaquine (PQ), while the other with halogenanilines
(Figure 1). Sharing the same conjugated C=C-CO system and a benzene ring, our compounds are
similar to cinnamic acid (trans-3-phenyl-2-propenoic acid) derivatives as well. Taking literature data
into account [22–24] and our previous experience with PQ derivatives [20,21,25–28], we have assumed
that the designed compounds have a high pharmacological potential. Here we report their synthesis,
evaluation of antimicrobial activity on a wide spectrum of bacteria, fungi and viruses, their biofilm
eradication ability, and finally, cytostatic activity against several human tumor cell lines.
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for activity, we h ve also prepared a series of analog us compounds without a double bond,
e.g., a series of succindiamides 5a–f (compound 5a is a reduced derivative of 4a, 5b of 4b etc.).
In both series f compounds, one of the amide bonds was achieved with the primary amino group
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Sche e 1. Synthesis of fu ardia ides 4a–f and succindia ides 5a–f.
New compounds are fully characterized by MS, IR, 1H and 13C NMR spectroscopic methods
and elemental analyses. Spectral data are consistent with the proposed structures and are given
in short in the Materials and Methods and in detail in the Supplementary Material. The presence
of carbonyl functional groups in compounds 4 and 5 was indicated by the appearance of strong
stretching vibration bands in IR spectra between ν 1677 and 1628 (amide I) and 1555 and 1515 cm–1
(amide II). PQ residue showed characteristic signals in 1H NMR spectra: hydrogen atom CH-15
occurred between δ 8.52 and 8.55, methoxy group at δ 3.82, the hydrogen attached to chiral carbon
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(CH-10) as a multiplet at δ 3.57–3.65, a methyl group at δ 1.19–1.22. NH-1 appeared as a singlet between
δ 9.98 and 10.75 ppm, NH-6 as a triplet at δ 7.86–8.55, while NH-12 as a doublet at δ 6.11–6.15 ppm.
13C spectra showed characteristic PQ signals at δ 54.92–54.98 (methoxy group), 46.19–47.02 (C-10),
38.46–39.23 (C-7), 33.37–33.45 (C-9), 25.70–25.99 (C-8), 20.14–20.21 (C-11) ppm and corresponding
signals in aromatic region. Two signals of carbonyl groups in fumardiamides 4a–f appeared between
161.17 and 163.34 ppm, while in succindiamides 5a–f between 170.35 and 171.18 ppm. The other two
succinic acid carbons (C-3 and C-4) appeared in the aliphatic region between 30.10 and 31.75, and
fumaric acid carbons connected by double bond were located very high between 132.11 and 134.66
ppm. CF3 groups in compounds 4e, 4f, 5e and 5f showed characteristic quartets at 121.32–127.05
with average J = 272 Hz, and the closest C-atom to trifluoromethyl quartets at 124–129 ppm with
J = 31 Hz. m-Fluorophenyl derivatives 4a and 5a showed doublets at 162 ppm and p-fluorophenyl
derivatives 4b and 5b doublets at 158 ppm (C-atom bearing fluorine) with a similar J-coupling constant
of 240 Hz, while two neighbouring C-atoms appeared at 105–110 ppm (average J = 21 Hz). C-atom
substituted with chloro atom appeared at 133 ppm (m-Cl) and 127 ppm (p-Cl). Chemical structures of
new compounds were also supported by mass spectroscopy. Molecular ion peaks corresponding to
expected relative molecular masses were obtained for all compounds.
Diamides 4 and 5 were subjected to in silico analysis to evaluate the diversity of the set
of compounds against topological polar surface area (TPSA) calculations and relevant drug-like
properties: number of atoms, molecular weight (MW), partition coefficient (log P), H-bond donor
(HBD), H-bond acceptor (HBA) and molecular refractivity (MR). The parameters are calculated with
the Chemicalize.org program [30] and presented in Table S1. All compounds are fully in agreement
with the Lipinski and Gelovani rules for prospective small molecular drugs (MW ≤ 500, log P ≤ 5,
number of H-bond donors ≤ 5, number of H-bond acceptors ≤ 10, TPSA < 140 Å2, MR within the
range of 40 and 130 cm3/mol, the number of atoms 20–70), although 4e,f and 5e,f have the highest
permitted relative molecular masses.
2.2. Biological Evaluation
2.2.1. Antibacterial and Antifungal Activity
The antimicrobial screening was assessed against a panel of Gram-positive bacteria (S. pneumoniae
MFBF 10373, S. aureus ATCC 6538, methicillin-resistant S. aureus MRSA 63718, SA 630 and SA 3202,
E. faecalis ATCC 29212 and three vancomycin-resistant Enterococci VRE 342 B, 365 and 725 B, B. cereus
ATCC 11778, and B. subtilis ATCC 6633), Gram-negative species (P. aeruginosa ATCC 27853, E. coli ATCC
10536, S. marcescens ATCC 10905, P. mirabilis MFBF 10430, A. baumannii MFBF 10913, and S. enteritidis
MFBF 11945), four Mycobacterium strains (M. tuberculosis H37Ra, M. smegmatis ATCC 700084, M. kansasii
DSM 44162, and M. marinum CAMP 5644) and fungi (two strains of C. albicans ATCC 90028 and CCM
8361, C. krusei CCM 8271, C. parapsilosis CCM 8260 and A. brasiliensis ATCC 16404). The results of
the antimicrobial screening of fumardiamides 4a–f are presented in Table 1 (the results for inactive
fumardiamides and succindiamides 5a–f are not shown). In general, Gram-positive bacteria, especially
S. pneumoniae and S. aureus ATCC 6538 were susceptible to 4b–f. Compounds 4a,b were active against
B. cereus as well. However, Gram-negative bacterium A. baumannii was the most susceptible among all
tested microorganisms: all compounds, except m-fluoro derivative 4a, showed selective antimicrobial
activity against this bacterium strain. Comparison of meta and para derivatives, e.g., a vs. b, c vs. d, e
vs. f revealed that in the most cases p-substituted derivatives were more active than the analogous
m-derivatives. p-Chlorofumardiamide 4d showed significant activity against three bacterial strains
(S. aureus, S. pneumoniae and A. baumannii), but also against C. albicans ATCC 90028, with minimum
inhibitory concentration (MIC) values ranging from 6.1 to 12.5 µg/mL. This compound, together with
p-fluoro and p-CF3 fumardiamides 4b,f showed antitubercular activity against M. marinum, while 4b,f
were active against M. tuberculosis as well.
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2.2.2. Biofilm Eradication Assay
We tested the susceptibility of different bacterial and yeast strains to fumardiamides 4a–f and
succindiamides 5a–f by determining minimum biofilm eradication concentrations (MBECs). The results
are presented in Table 2. Again, fumardiamides 4 were much more active than the analogous
succindiamides 5. The most active compounds were 4a and 4b. Two microorganisms, namely
E. faecalis and S. aureus showed high susceptibility to all fumardiamides, while E. coli, S. pneumoniae
and P. aeruginosa were susceptible to five out of six fumardiamides. A high biofilm eradication
potential of fumardiamides might be explained by the reaction of Michael acceptors with cysteine
thiol, which could prevent disulfide bond formation. It is a well-known fact that cysteine homeostasis
impacts biofilm formation and production of extracellular matrix components, as well as folding
and stability of extracytoplasmic proteins [31]. They are also crucial for dental plaque formation,
autolysis, extracellular DNA release, genetic competence, bacteriocin production and stabilization of
outer membrane porin proteins [32].
2.2.3. Antiviral Evaluation
Compounds 4a–f and 5a–f were evaluated against a broad variety of viral infections including
herpes simplex viruses, vaccinia virus, adenovirus-2, human coronavirus (229E), vesicular stomatitis
virus, coxsackie virus B4, respiratory syncytial virus, para-influenza-3 virus, reovirus-1, sindbis virus,
coxsackie virus B4, Punta Toro virus and yellow fever virus. Only fumardiamides with m-chloro and
m-trifluoromethyl aniline residues, namely 4c and 4e, showed significant antiviral activity against
reovirus-1, sindbis virus and Punta Toro virus with EC50 = 3.1–5.5 µM (EC50 = concentration required to
reduce virus-induced cytopathogenicity by 50%). Compound 4e was also active against coxsackie virus
B4 (EC50 = 3.1 µM). However, their selectivity index (SI), e.g., minimum cytotoxicity concentration
(MCC) and EC50 ratio, was quite low (1.8–3.7). Cytotoxicity and antiviral activity of fumardiamides
4a–f in Vero cell cultures are displayed in Table 3 (data for HEL (human erythroleukemia cell line),
Hela (cervical carcinoma cell line) and Madin-Darby Canine Kidney cells (MDCK) cultures are not
shown, as well as data for inactive succindiamides 5a–f).
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Table 1. Antimicrobial susceptibility assay in vitro (minimum inhibitory concentration (MIC) determination) for compounds 4a–f.
Compd.
MIC (µg/mL)
Staphylococcus
aureus
ATCC 6538
Streptococcus
pneumoniae
MFBF 10373
Enterococcus
faecalis
ATCC 29212
Bacillus cereus
ATCC 11778
Bacillus subtilis
ATCC 6633
Acinetobacter
baumannii
MFBF 10913
Mycobacterium
tuberculosis
H37Ra
Mycobacterium
marinum
CAMP 5644
Candida
albicans
ATCC 90028
4a >100 >100 128 >100 50 >100 128 >256 >100
4b 12.5 12.5 64 25 25 25 32 64 >100
4c 12.5 25 256 25 50 25 128 128 >100
4d 6.1 12.5 64 >100 >100 12.5 128 64 12.5
4e 50 50 128 >100 >100 25 128 256 >100
4f 50 50 64 >100 >100 25 64 64 >100
PQ 1 50 50 128 70 80 50 256 256 >100
TC 2 0.3 0.3 – 0.3 0.3 3 – – –
CIP 3 – – – – – – 16.0 0.3 –
INH 4 – – – – – – 5.0 64.0 –
RIF 5 – – – – – – 8.7 2.2 –
Amph 6 – – – – – – – – 0.5
1 PQ—primaquine; 2 TC—tetracycline; 3 CIP—ciprofloxacin; 4 INH—isoniazid; 5 RIF—rifampicin; 6 Amph—amphotericin B.
Table 2. Sensitivity of microbial strains to fumardiamides 4a–f expressed as minimum biofilm eradication concentrations (MBEC).
Compd.
MBEC (µg/mL)
Staphylococcus
aureus
ATCC 6538
Streptococcus
pneumonia
MFBF 10373
Enterococcus
faecalis
ATCC 29212
Bacillus cereus
ATCC 11778
Bacillus subtilis
ATCC 6633
Escherichia coli
ATCC 10536
Pseudomonas
aeruginosa
ATCC 27853
Serratia
marcescens
ATCC 10905
Proteus
mirabilis
MFBF 10430
Salmonella
enteritidis
MFBF 11945
Acinetobacter
baumannii
MFBF 10913
4a 12.5 12.5 25 >100 50 100 25 25 >100 >100 6.3
4b 12.5 25 25 25 25 50 12.5 >100 25 >100 25
4c 12.5 100 25 25 50 50 50 >100 >100 >100 100
4d 25 50 50 >100 >100 50 >100 >100 >100 >100 100
4e 50 50 50 >100 >100 50 50 >100 >100 >100 100
4f 25 50 50 >100 >100 50 25 >100 >100 >100 100
PQ 1 50 70 >100 70 80 65 65 >100 >100 70 50
Gen 2 12.5 25 50 50 50 25 50 50 50 50 25
1 PQ—primaquine; 2 Gen—gentamycin.
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Table 3. Cytotoxicity and antiviral activity of fumardiamides 4a–f evaluated in Vero cell cultures.
Compd.
Cytotoxicity EC50 1 (µM)
CC50 2 MCC 3
Para-Influenza-3 Virus Reovirus-1 Sindbis Virus Coxsackie Virus B4 Punta Toro Virus Yellow Fever Virus
MTS Visual CPEScore MTS
Visual CPE
Score MTS
Visual CPE
Score MTS
Visual CPE
Score MTS
Visual CPE
Score MTS
Visual CPE
Score
4a 46.9 – >50 – >50 – >50 – >50 – >50 – >50 –
4b >50 – >50 – >50 – >50 – >50 – >50 – >50 –
4c >50 10 >50 >50 3.8 >50 3.0 >50 >50 >50 5.5 >50 >50 >50
4d >50 – >50 – >50 – >50 – >50 – >50 – >50 –
4e >50 10 >50 >50 3.1 >50 5.3 4.2 3.1 2.7 5.4 >50 >50 >50
4f >50 – >50 – >50 – >50 – >50 – >50 – >50 –
PQ >50 – >50 – >50 – >50 – >50 – >50 – >50 –
DS-10.000 4 >100 >100 >100 >100 >100 >100 4.0 10 >100 34 16 8.9 1.6 >100
RIB 5 >250 >250 73 111 107 126 >250 11 >250 >250 85 111 119 >250
MPA 6 >100 >100 1.0 0.8 0.6 0.8 12 1.7 >100 >100 11 8.9 0.5 0.8
1 Concentration required to reduce virus-induced cytopathicity by 50%, as determined by visual scoring of the cytopathic effect (CPE), or by measuring the cell viability with the
colorimetric formazan-based 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay; 2 Concentration that causes 50% cytotoxic effect,
as determined by measuring the cell viability with the colorimetric formazan-based MTS assay; 3 Minimum cytotoxic concentration, i.e., the minimum concentration that causes a
microscopically detectable alteration of normal cell morphology; 4 Concentration in µg/mL; 5 RIB—ribavirin; 6 MPA—mycophenolic acid. All experiments were performed in duplicate.
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2.2.4. Cytostatic Activity
To gain insight into cytotoxicity of newly synthesized compounds 4a–f and 5a–f, their cytostatic
activity was evaluated in vitro against a panel of nine different human cancer cell lines, representing
various solid tumor types including pancreatic adenocarcinoma (Capan-1), chronic myeloid
leukemia (Hap1), colorectal carcinoma (HCT-116), lung carcinoma (NCI-H460), acute lymphoblastic
leukemia (DND-41), acute myeloid leukemia (HL-60), chronic myeloid leukemia (K-562), multiple
myeloma (MM.1S) and non-Hodgkin lymphoma (Z-138). Succindiamides 5a–f were completely
inactive, while free fumardiamides showed activity towards the selected tumor cell lines (Table 4).
Fumardiamide 4a with m-fluoroaniline moiety showed cytostatic activity against all tested cell lines,
with IC50 values from 5.7 to 31.2 µM (IC50 = the lowest concentration resulting in 50% growth
inhibition). DND-41 cell line was susceptible to all three m-substituted derivatives, e.g., 4a, 4c and 4f
(IC50 values between 6.7 and 8.9 µM). HL-60 and Z-138 cell lines were also susceptible to compound
4a (IC50 values 5.7 and 8.4 µM, respectively).
Table 4. Antiproliferative screening of fumardiamides 4a–f in diverse human tumor cell lines.
Compd.
IC50 (µM)
Capan-1 Hap1 HCT-116 NCI-H460 DND-41 HL-60 K-562 MM.1S Z-138
4a 16.9 19.3 22.3 15.5 6.7 5.7 31.2 13.0 8.4
4b 50.5 66.4 >100 29.1 >100 >100 70.5 >100 >100
4c 69.9 >100 73.0 43.7 8.4 >100 >100 >100 46.5
4d 91.8 >100 >100 >100 >100 >100 >100 >100 >100
4e 56.5 >100 >100 34.2 8.9 >100 71.2 >100 68.4
4f 79.4 >100 >100 >100 >100 >100 >100 >100 >100
PQ 1 18.7 42.7 30.9 52.6 11.4 2.2 35.2 28.3 7.1
DXT 2 0.75 1.17 7.66 1.30 0.94 1.24 1.22 3.38 5.42
EPEG 3 0.15 0.04 1.35 0.09 0.03 0.03 0.01 0.97 0.02
STS 4 0.66 3.56 0.78 1.66 6.96 13.10 0.23 1.61 0.40
1 PQ—primaquine; 2 DXT—docetaxel (nM); 3 EPEG—etoposide; 4 STS—staunoporin (nM). All compounds were
tested with duplicate data points and averaged.
2.2.5. Interaction with Glutathione (GSH)
Glutathione (GSH) is an important compound present in most mammalian cells, a tripeptide,
with the central amino acid cysteine bearing thiol group, which scavenges carcinogenic compounds
by conjugate addition and protects from oxidative damage [1]. In the drug development process,
it is usual to evaluate the Michael acceptor–GSH interaction [33]. That is why the final step in our
research was to study the interaction of fumarmides with GSH. Fumardiamide 4b (1.25 µM) was
incubated with GSH (125 µM) in ammonium formate buffer (pH = 7.4) containing 10% acetonitrile
at 37 ◦C for 216 h. The MS analysis confirmed the consumption of 4b with GSH. However, the rate
of GSH addition was slow and incomplete, as only 18.3% of 4b reacted in the monitored period
(See Supporting Material).
3. Materials and Methods
3.1. Chemistry
3.1.1. Materials and General Methods
Melting points were determined on an SMP3 apparatus (Barloworld Scientific, UK) in open
capillaries and were uncorrected. IR spectra were recorded on Spectrum One FT-IR (Perkin-Elmer,
UK) and UV-Vis spectra on Lambda 20 double-beam spectrophotometers (Perkin-Elmer, UK).
NMR 1H and 13C spectra were recorded at 25 ◦C on an NMR Avance 600 spectrometer (Bruker,
Germany) at 300.13 or 600.13 and 75.47 or 150.9 MHz for 1H and 13C nuclei, respectively. Chemical
shifts (δ) were reported in parts per million (ppm) relative to tetramethylsilane in the 1H and the
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dimethyl sulfoxide residual peak as a reference in the 13C NMR spectra (39.51 ppm). Coupling
constants (J) were reported in hertz (Hz). Mass spectra were collected on an HPLC-MS/MS
instrument (HPLC, Agilent Technologies 1200 Series; MS, Agilent Technologies 6410 Triple Quad)
using electrospray ionization in positive mode. Elemental analyses were performed on a CHNS
LECO analyzer (LECO Corporation, USA). All compounds were routinely checked by thin-layer
chromatography (TLC) with Merck silica gel 60F-254 glass plates using appropriate solvent systems.
Spots were visualized by short-wave UV light and iodine vapour. Column chromatography was
performed on silica gel 0.063–0.200 mm. All chemicals and solvents were of analytical grade and
purchased from commercial sources. PQ diphosphate, 4-methoxy-4-oxobutanoic acid (mono-methyl
succinate), (E)-4-ethoxy-4-oxobut-2-enoic acid (mono-ethyl fumarate), 3-fluoroaniline, 4-fluoroaniline,
3-chloroaniline, 4-chloroaniline, 3-trifluoromethylaniline, 4-trifluoromethylaniline, DIEA, and HATU
were purchased from Sigma-Aldrich. PQ was prepared from PQ diphosphate prior to use. All reactions
with PQ were run light protected.
3.1.2. General Procedure for the Synthesis of Esters 2a,b
PQ-succinamide and fumaramide monoesters 2a,b were prepared by condensation of PQ base
with mono-methyl succinate (1a) or mono-ethyl fumarate (1b), following the previously described
procedure [29].
3.1.3. General Procedure for the Synthesis of Carboxylic Acids 3a,b
Carboxylic acids 3a,b were prepared by hydrolysis of esters 2a,b with lithium hydroxide following
the previously described procedure [29].
3.1.4. General Procedure for the Synthesis of Fumardiamides 4a–f and Succindiamides 5a–f
A solution of 0.27 mmol of 3a or 3b, 0.068 g (0.54 mmol) DIEA and 0.103 g (0.27 mmol) HATU
in 6 mL of dichloromethane was stirred at room temperature. After 10 min, 0.297 mmol of the
corresponding halogenaniline was added. The reaction mixture was stirred for 2–3 h at room
temperature, evaporated under reduced pressure, dissolved in 8 mL ethyl acetate and extracted
3 times with water. The organic layer was dried over sodium sulfate, filtered and evaporated under
reduced pressure.
(2E)-N-(3-Fluorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}but-2-enediamide (4a). From the
reaction of 0.096 g acid 3a and 0.033 g (0.297 mmol) 3-fluoroaniline and after purification by column
chromatography (mobile phase dichloromethane/methanol 9.5:0.5) and crystallization from ether,
0.041 g (34%) of 4a was obtained; mp 203–204 ◦C; IR (ATR): νmax 3388, 3319, 3269, 3080, 2961, 2935,
2866, 1630, 1554, 1520, 1452, 1387, 1334, 1201, 1158, 782, 680 cm–1; 1H NMR (DMSO-d6) δ 10.63 (s, 1H),
8.55–8.53 (dd, 1H, J = 1.6, 4.2), 8.52 (t, 1H, J = 5.4), 8.09–8.06 (dd, 1H, J = 1.5, 8.3), 7.69 (d, 2H, J = 11.7),
7.45–7.41 (m, 1H), 7.39–7.36 (m, 2H), 7.06–7.96 (m, 2H), 6.96–6.92 (m, 1H), 6.47 (d, 1H, J = 2.4), 6.28 (d, 1H,
J = 2.4), 6.15 (d, 1H, J = 8.8), 3.82 (s, 3H), 3.70–3.61 (m, 1H), 3.24–3.18 (m, 2H), 1.74–1.64, 1.63–1.52 (2m,
4H), 1.22 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 163.25, 162.62, 162.09 (d, J = 242.0), 159.00, 144.63,
144.23, 140.50 (d, J = 11.5), 134.79, 134.52, 134.40, 132.28, 130.50 (d, J = 9.5), 129.57, 122.09, 115.14, 110.28,
106.13 (d, J = 27.2), 96.14, 91.62, 54.96, 46.97, 38.95, 33.45, 25.77, 20.21; MS/MS m/z 451.1 (M + 1)+;
Anal. Calcd. for C25H27FN4O3: C, 66.65; H, 6.04; N, 12.44. Found: C, 66.32; H, 6.30; N, 12.49.
(2E)-N-(4-Fluorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}but-2-enediamide (4b). From the
reaction of 0.096 g acid 3a and 0.033 g (0.297 mmol) 4-fluoroaniline and after purification by column
chromatography (mobile phase dichloromethane/methanol 9.5:0.5) and crystallization from ether,
0.071 g (58%) of 4b was obtained; mp 226–227 ◦C; IR (ATR): νmax 3386, 3294, 3072, 2963, 2928, 2863, 1635,
1548, 1513, 1452, 1391, 1330, 1212, 1160, 1051, 973, 829, 673 cm–1; 1H NMR (DMSO-d6) δ 10.49 (s, 1H),
8.55–8.53 (dd, 1H, J = 1.6, 4.2), 8.52 (t, 1H, J = 5.4), 8.09–8.06 (dd, 1H, J = 1.5, 8.3), 7.72–7.68 (dd, 2H,
J = 5.0, J = 8.9), 7.45–7.41 (m, 1H), 7.18 (t, 2H, J = 8.8), 7.05–6.93 (m, 2H), 6.47 (d, 1H, J = 2.1), 6.28 (d,
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1H, J = 2.1), 6.15 (d, 1H, J = 8.8), 3.82 (s, 3H), 3.69–3.61 (m, 1H), 3.24–3.18 (m, 2H), 1.74–1.64, 1.63–1.52
(2m, 4H), 1.22 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 163.34, 162.21, 159.00, 158.26 (d, J = 240.0), 144.63,
144.23, 135.22, 134.79, 134.53, 133.98, 132.52, 129.58, 122.09, 121.05 (d, J = 7.6), 115.44 (d, J = 21.9), 96.14,
91.62, 54.96, 46.97, 38.95, 33.45, 25.79, 20.21; MS/MS m/z 451.1 (M + 1)+; Anal. Calcd. for C25H27FN4O3:
C, 66.65; H, 6.04; N, 12.44. Found: C, 66.47; H, 6.38; N, 12.35.
(2E)-N-(3-Chlorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}but-2-enediamide (4c). From the
reaction of 0.096 g acid 3a and 0.038 g (0.297 mmol) 3-chloroaniline and after purification by column
chromatography (mobile phase dichloromethane/methanol 9.5:0.5) and crystallization from ether,
0.053 g (42%) of 4c was obtained; mp 187–188 ◦C; IR (ATR): νmax 3381, 3298, 3068, 2959, 2928, 2863,
1635, 1591, 1521, 1465, 1419, 1386, 1331, 1210, 1163, 976, 821, 783, 670 cm–1; 1H NMR (DMSO-d6)
δ 10.59 (s, 1H), 8.54–8.53 (dd, 1H, J = 1.5, 4.1), 8.50 (t, 1H, J = 5.5), 8.08–8.06 (dd, 1H, J = 1.4, 8.2),
7.90 (s, 1H), 7.51 (d, 1H, J = 8.1), 7.43–7.41 (m, 1H), 7.37 (t, H, J = 8.1), 7.16–7.14 (dd, 1H, J = 1.2, J = 8.0),
7.00 (q, 2H, J = 15.1), 6.47 (d, 1H, J = 2.4), 6.28 (d, 1H, J = 2.3), 6.14 (d, 1H, J = 8.8), 3.82 (s, 3H), 3.67–3.63
(m, 1H), 3.23–3.20 (m, 2H), 1.73–1.67, 1.63–1.53 (2m, 4H), 1.22 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ
163.21, 162.60, 158.97, 144.60, 144.19, 140.19, 134.74, 134.50, 134.41, 133.10, 132.19, 130.48, 129.54, 123.45,
122.03, 118.74, 117.72, 96.11, 91.63, 54.93, 46.98, 39.23, 33.44, 25.72, 20.18; MS/MS m/z 467.0 (M+1)+;
Anal. tCalcd. for C25H27ClN4O3: C, 64.30; H, 5.83; N, 12.00. Found: C, 64.21; H, 6.05; N, 11.78.
(2E)-N-(4-Chlorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}but-2-enediamide (4d). From the
reaction of 0.096 g acid 3a and 0.038 g (0.297 mmol) 4-chloroaniline and after purification by column
chromatography (mobile phase cyclohexane/ethyl acetate/methanol 3:1:0.5) and crystallization from
ether, 0.062 g (49%) of 4d was obtained; mp 223–226 ◦C; IR (ATR): νmax 3381, 3289, 3071, 2959, 2931,
2864, 1640, 1526, 1452, 1388, 1331, 1210, 1163, 1094, 1049, 973, 822, 787, 686, 631, 507 cm–1; 1H NMR
(DMSO-d6) δ 10.56 (s, 1H), 8.55–8.53 (dd, 1H, J = 1.7, 4.2), 8.50 (t, 1H, J = 5.6), 8.09–8.06 (dd, 1H, J = 1.6,
8.3), 7.72–7.68 (m, 2H), 7.45–7.37 (m, 3H), 7.06–6.94 (m, 2H), 6.47 (d, 1H, J = 2.5), 6.27 (d, 1H, J = 2.4),
6.14 (d, 1H, J = 8.8), 3.82 (s, 3H), 3.69–3.60 (m, 1H), 3.24–3.18 (m, 2H), 1.74–1.64, 1.63–1.51 (2m, 4H),
1.22 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 163.29, 162.43, 159.00, 144.63, 144.23, 137.76, 134.79, 134.52,
134.21, 132.38, 129.57, 128.75, 127.36, 122.09, 120.84, 96.14, 91.61, 54.96, 46.97, 38.82, 33.44, 25.77, 20.21;
MS/MS m/z 467.0 (M+1)+; Anal. Calcd. for C25H27ClN4O3: C, 64.30; H, 5.83; N, 12.00. Found: C, 64.21;
H, 5.56; N, 11.83.
(2E)-N′-{4-[(6-Methoxyquinolin-8-yl)amino]pentyl}-N-[3-(trifluoromethyl)phenyl]but-2-enediamide (4e).
From the reaction of 0.096 g acid 3a and 0.048 g (0.297 mmol) 3-trifluoroaniline and after purification
by column chromatography (mobile phase dichloromethane/methanol 9.5:0.5) after crystallization
from acetone/water, 0.042 g (31%) of 4e was obtained; mp 149–150 ◦C; IR (ATR): νmax 3399, 3357,
3282, 3094, 2960, 2935, 2867, 1651, 1621, 1563, 1526, 1452, 1388, 1331, 1168, 1122, 973, 893, 788, 694
cm–1; 1H NMR (DMSO-d6) δ 10.75 (s, 1H), 8.55–8.52 (m, 2H), 8.18 (s, 1H), 8.08–8.06 (dd, 1H, J = 1.1,
8.2), 7.83 (d, 1H), 7.59 (t, 1H, J = 7.9), 7.45–7.42 (m, 2H), 7.00–6.98 (q, 2H, J = 15.1), 6.47 (d, 1H, J
= 2.4), 6.28 (d, 1H, J = 2.0), 6.15 (d, 1H, J = 8.7), 3.82 (s, 3H), 3.67–3.63 (m, 1H), 3.23–3.20 (m, 2H),
1.73–1.67, 1.63–1.53 (2m, 4H), 1.22 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 163.19, 162.81, 158.99, 144.62,
144.21, 139.54, 134.77, 134.55, 134.52, 132.15, 130.09, 129.56, 129.82–129.19 (q, J = 31.7), 126.73–121.32
(q, J = 273.3), 122.88, 122.07, 120.09, 115.33, 96.13, 91.62, 54.95, 46.19, 39.23, 33.45, 25.76, 20.20; MS/MS
m/z 501.1 (M+1)+; Anal. Calcd. for C26H27F3N4O3: C, 62.39; H, 5.44; N, 11.19. Found: C, 62.25; H, 5.76;
N, 11.08.
(2E)-N′-{4-[(6-Methoxyquinolin-8-yl)amino]pentyl}-N-[4-(trifluoromethyl)phenyl]but-2-enediamide (4f).
From the reaction of 0.096 g acid 3a and 0.048 g (0.297 mmol) 4-trifluoroaniline and after crystallization
from ether, 0.046 g (34%) of 4f was obtained; mp 189–191 ◦C; IR (ATR): νmax 3387, 3309, 3071, 2963,
2932, 1636, 1527, 1457, 1417, 1390, 1328, 1213, 1166, 1122, 1065, 970, 832, 681 cm–1; 1H NMR (DMSO-d6)
δ 10.75 (s, 1H), 8.54–8.53 (m, 1H), 8.51 (t, 1H, J = 5.3), 8.07 (d, 1H, J = 8.2), 7.88 (d, 2H, J = 8.5),
7.71 (d, 2H, J = 8.5), 7.43–7.41 (m, 1H), 7.07–6.99 (q, 2H, J = 15.1), 6.47 (d, 1H, J = 2.2), 6.28 (d, 1H,
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J = 2.2), 6.14 (d, 1H, J = 8.7), 3.82 (s, 3H), 3.67–3.63 (m, 1H), 3.23–3.20 (dd, 2H, J = 6.1, 12.1), 2.59 (t, 2H,
J = 7.0), 1.73–1.67, 1.61–1.53 (2m, 4H), 1.22 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 161.17, 162.83, 158.97,
144.60, 144.17, 142.28, 134.72, 134.66, 134.50, 132.11, 129.53, 126.95–121.55 (q, J = 271.6), 126.11–126.04
(q, J = 3.0), 124.02–123.39 (q, J = 31.7), 122.02, 119.26, 96.10, 91.63, 54.92, 46.96, 38.80, 33.43, 25.70, 20.17;
MS/MS m/z 501.1 (M+1)+; Anal. Calcd. for C26H27F3N4O3: C, 62.39; H, 5.44; N, 11.19. Found: C, 62.17;
H, 5.61; N, 11.40.
N-(3-Fluorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}butanediamide (5a). From the reaction
of 0.097 g acid 3b and 0.033 g (0.297 mmol) 3-fluoroaniline and after purification by column
chromatography (mobile phase dichloromethane/methanol 9.5:0.5), 0.077 g (63%) of 5a was obtained;
mp 140–142 ◦C; IR (ATR): νmax 3391, 3283, 3145, 3080, 2959, 2926, 1744, 1646, 1615, 1555, 1507, 1387,
1224, 1202, 1167, 1157, 838, 815, 786, 681 cm–1; 1H NMR (DMSO-d6) δ 10.13 (s, 1H), 8.54–8.53 (dd, 1H,
J = 1.7, 4.2), 8.08–8.06 (dd, 1H, J = 1.6, 8.3), 7.86 (t, 1H, J = 5.6), 7.60–7.58 (m, 1H), 7.43–7.41 (m, 1H),
7.31–7.27 (m, 2H), 6.85–6.81 (m, 1H), 6.47 (d, 1H, J = 2.5), 6.26 (d, 1H, J = 2.5), 6.11 (d, 1H, J = 8.7),
3.82 (s, 3H), 3.64–3.59 (m, 1H), 3.10–3.03 (m, 2H), 2.55 (t, 2H, J = 7.2), 2.37 (t, 2H, J = 7.2), 1.67–1.63,
1.55–1.45 (2m, 4H), 1.19 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 170.86, 162.10 (d, J = 240.1), 158.98,
144.61, 144.19, 141.03 (d, J = 13.1), 134.75, 134.51, 130.19 (d, J = 9.0), 129.55, 122.05, 114.55, 109.22 (d, J =
20.1), 105.61, 96.07, 91.59, 54.94, 46.99, 38.46, 33.38, 31.75, 30.16, 25.95, 20.15; MS/MS m/z 453.3 (M+1)+;
Anal. Calcd. for C25H29FN4O3: C, 66.35; H, 6.46; N, 12.38. Found: C, 66.25; H, 6.50; N, 12.20.
N-(4-Fluorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}butanediamide (5b). From the reaction
of 0.097 g acid 3b and 0.033 g (0.297 mmol) 4-fluoroaniline and after purification by column
chromatography (mobile phase dichloromethane/methanol 9.5:0.5) and crystallization from ether,
0.098 g (80%) of 5b was obtained; mp 118–120 ◦C; IR (ATR): νmax 3391, 3283, 3145, 3080, 2959, 2926,
1744, 1646, 1615, 1555, 1507, 1387, 1224, 1202, 1167, 1157, 838, 815, 786, 681 cm–1; 1H NMR (DMSO-d6) δ
9.98 (s, 1H), 8.55–8.53 (dd, 1H, J = 1.6, 4.2), 8.09–8.06 (dd, 1H, J = 1.5, 8.3), 7.87 (t, 1H, J = 5.5), 7.62–7.57
(m, 2H), 7.45–7.40 (m, 1H), 7.14–7.08 (m, 2H), 6.47 (d, 1H, J = 2.4), 6.26 (d, 1H, J = 2.4), 6.12 (d, 1H,
J = 8.8), 3.82 (s, 3H), 3.65–3.57 (m, 1H), 3.10–3.04 (m, 2H), 2.54 (t, 2H, J = 7.1), 2.37 (t, 2H, J = 7.0),
1.69–1.59, 1.58–1.43 (2m, 4H), 1.19 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 170.96, 170.35, 159.00, 157.72
(d, J = 246.3), 144.63, 144.22, 135.76, 134.79, 134.52, 129.57, 122.09, 120.53 (d, J = 7.8), 115.14 (d, J = 22.1),
96.09, 91.58, 54.97, 47.00, 38.48, 33.39, 31.66, 30.34, 25.99, 20.17; MS/MS m/z 453.4 (M+1)+; Anal. Calcd.
for C25H29FN4O3: C, 66.35; H, 6.46; N, 12.38. Found: C, 66.53, H, 6.29; N, 12.55.
N-(3-Chlorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}butanediamide (5c). From the reaction
of 0.097 g acid 3b and 0.038 g (0.297 mmol) 3-chloroaniline and after purification by column
chromatography (mobile phase cyclohexane/ethyl acetate/methanol 3:1:0.5) and crystallization from
ether, 0.062 g (49%) of 5c was obtained; mp 156–158 ◦C; IR (ATR): νmax 3390, 3287, 3242, 3180, 3102,
3074, 2962, 2922, 2856, 1738, 1650, 1612, 1591, 1572, 1539, 1516, 1422, 1388, 1202, 1066, 816, 787, 698, 682
cm–1; 1H NMR (DMSO-d6) δ 10.11 (s, 1H), 8.54–8.53 (dd, 1H, J = 1.6, 4.2), 8.08–8.06 (dd, 1H, J = 1.6,
8.3), 7.86 (t, 1H, J = 5.5), 7.81 (t, 1H, J = 2.0), 7.43–7.41 (m, 2H), 7.31–7.28 (m, 1H), 7.07–7.05 (m, 1H),
6.47 (d, 1H, J = 2.5), 6.25 (d, 1H, J = 2.5), 6.11 (d, 1H, J = 8.2), 3.82 (s, 3H), 3.63–3.59 (m, 1H), 3.10–3.03 (m,
2H), 2.55 (t, 2H, J = 7.1), 2.37 (t, 2H, J = 7.2), 1.67–1.63, 1.56–1.44 (2m, 4H), 1.19 (d, 3H, J = 6.3); 13C NMR
(DMSO-d6) δ 170.89, 170.85, 158.98, 144.60, 144.19, 140.73, 134.77, 134.49, 132.97, 130.29, 129.55, 122.51,
122.06, 118.31, 117.19, 96.08, 91.59, 54.95, 46.99, 38.46, 33.38, 31.74, 30.16, 25.96, 20.16; MS/MS m/z 469.2
(M+1)+; Anal. Calcd. for C25H29ClN4O3: C, 64.03; H, 6.23; N, 11.95. Found: C, 63.91; H, 6.33; N, 11.70.
N-(4-Chlorophenyl)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}butanediamide (5d). From the reaction
of 0.097 g acid 3b and 0.038 g (0.297 mmol) 3-chloroaniline and after purification by column
chromatography (mobile phase dichloromethane/methanol 9.5:0.5) and crystallization from ether,
0.076 g (60%) of 5d was obtained; mp 152–153 ◦C; IR (ATR): νmax 3390, 3287, 3242, 3180, 3102, 3074,
2962, 2922, 2856, 1738, 1650, 1612, 1591, 1572, 1539, 1516, 1422, 1388, 1202, 1066, 816, 787, 698, 682
cm–1; 1H NMR (DMSO-d6) δ 10.07 (s, 1H), 8.55–8.53 (dd, 1H, J = 1.5, 4.2), 8.10–8.07 (dd, 1H, J = 1.4,
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8.3), 7.88 (t, 1H, J = 5.4), 7.61 (d, 2H, J = 8.9), 7.45–7.41 (m, 1H), 7.32 (d, 2H, J = 8.9), 6.48 (d, 1H, J = 2.3),
6.26 (d, 1H, J = 2.3), 6.13 (bs, 1H), 3.81 (s, 3H), 3.63–3.57 (m, 1H), 3.09–3.03 (m, 2H), 2.55 (t, 2H, J = 7.4),
2.39 (t, 2H, J = 7.0), 1.70–1.59, 1.58–1.43 (2m, 4H), 1.19 (d, 3H, J = 6.3); 13C NMR (DMSO-d6) δ 170.92,
170.64, 159.01, 144.55, 144.18, 138.28, 134.89, 134.42, 129.59, 128.51, 126.33, 122.09, 120.37, 96.19, 91.63,
54.98, 47.02, 38.47, 33.37, 31.73, 30.23, 25.98, 20.15 (11); MS/MS m/z 469.3 (M+1)+; Anal. Calcd. for
C25H29ClN4O3: C, 64.03; H, 6.23; N, 11.95. Found: C, 64.35; H, 6.57; N, 12.13.
N′-{4-[(6-Methoxyquinolin-8-yl)amino]pentyl}-N-[3-(trifluoromethyl)phenyl]butanediamide (5e). From the
reaction of 0.097 g acid 3b and 0.048 g (0.297 mmol) 3-trifluoromethylaniline and after purification by
column chromatography (mobile phase dichloromethane/methanol 9.5:0.5) and crystallization from
ether, 0.122 g (90%) of 5e was obtained; mp 146–149 ◦C; IR (ATR): νmax 3394, 3302, 3263, 3216, 3164,
3097, 2963, 2928, 2859, 1651, 1617, 1562, 1518, 1450, 1389, 1331, 1265, 1173, 1127, 1064, 894, 816 cm–1; 1H
NMR (DMSO-d6) δ 10.26 (s, 1H), 8.54–8.53 (dd, 1H, J = 1.6, 4.2), 8.11 (s, 1H), 8.08–8.06 (dd, 1H, J = 1.6,
8.3), 7.88 (t, 1H, J = 5.5), 7.74 (d, 1H, J = 8.1), 7.52 (t, 1H, J = 8.0), 7.43–7.41 (m, 1H), 7.36 (d, 1H, J = 7.8),
6.47 (d, 1H, J = 2.5), 6.25 (d, 1H, J = 2.5), 6.11 (d, 1H, J = 8.7), 3.82 (s, 3H), 3.63–3.58 (m, 1H), 3.10–3.04 (m,
2H), 2.57 (t, 2H, J = 7.2), 2.41 (t, 2H, J = 7.2), 1.67–1.63, 1.56–1.44 (2m, 4H), 1.19 (d, 3H, J = 6.3); 13C NMR
(DMSO-d6) δ 171.11, 170.84, 158.98, 144.61, 144.19, 140.03, 134.75, 134.50, 129.83, 129.55, 129.67–129.04
(q, J = 31.9), 126.81–121.40 (q, J = 269.8), 122.33, 122.05, 119.14, 114.88, 96.06, 91.58, 54.94, 46.98, 38.46,
33.38, 31.72, 30.11, 25.96, 20.14; MS/MS m/z 503.3 (M+1)+; Anal. Calcd. for C26H29F3N4O3: C, 62.14; H,
5.82; N, 11.15. Found: C, 62.25; H, 5.99; N, 11.08.
N′-{4-[(6-Methoxyquinolin-8-yl)amino]pentyl}-N-[4-(trifluoromethyl)phenyl]butanediamide (5f). From the
reaction of 0.097 g acid 3b and 0.048 g (0.297 mmol) 4-trifluoromethylaniline and after purification by
column chromatography (mobile phase dichloromethane/methanol 9.5:0.5), 0.068 g (50%) of 5f was
obtained; mp 163–165 ◦C; IR (ATR): νmax 3387, 3287, 3256, 3198, 3123, 3071, 2963, 2925, 2859, 1652, 1614,
1547, 1515, 1452, 1419, 1389, 1327, 1264, 1169, 1124, 1064, 846, 784 cm–1; 1H NMR (DMSO-d6) δ 10.31
(s, 1H), 8.54–8.52 (dd, 1H, J = 1.5, 4.2), 8.09–8.06 (dd, 1H, J = 1.5, 8.3), 7.89 (t, 1H, J = 5.3), 7.79 (d, 2H,
J = 8.5), 7.63 (d, 2H, J = 8.7), 7.44–7.40 (m, 1H), 6.47 (d, 1H, J = 2.4), 6.25 (d, 1H, J = 2.4), 6.11 (d, 1H,
J = 8.7), 3.82 (s, 3H), 3.65–3.57 (m, 1H), 3.09–3.04 (m, 2H), 2.59 (t, 2H, J = 7.0), 2.40 (t, 2H, J = 7.0),
1.71–1.58, 1.57–1.43 (2m, 4H), 1.19 (d, 3H, J = 6.2); 13C NMR (DMSO-d6) δ 171.18, 170.86, 158.99, 144.61,
144.20, 142.83, 134.77, 134.51, 129.55, 125.95, 127.05–121.68 (q, J = 274.2), 123.15-122.52 (q, J = 28.2),
122.06, 118.69, 96.08, 91.59, 54.95, 46.99, 38.47, 33.38, 31.79, 30.10, 25.96, 20.14; MS/MS m/z 503.3 (M+1)+;
Anal. Calcd. for C26H29F3N4O3: C, 62.14; H, 5.82; N, 11.15. Found: C, 62.39; H, 5.76; N, 11.41.
3.2. Biological Evaluation
3.2.1. In Vitro Antibacterial Susceptibility Assay (MIC Determination)
(a) Staphylococci and Enterococci: The synthesized compounds were evaluated for in vitro
antibacterial activity against representatives of multidrug-resistant bacteria and clinical isolates of
methicillin-resistant Staphylococcus aureus (MRSA) 63718, SA 630 and SA 3202, that were obtained from
the National Institute of Public Health (Prague, Czech Republic). S. aureus ATCC 29213 was used as
a reference and quality control strain. In addition, all the compounds were tested for their activity
against vancomycin-susceptible Enterococcus faecalis ATCC 29212 as a reference strain and three isolates
from American crows of vanA-carrying vancomycin-resistant E. faecalis (VRE) 342B, 368 and 725B [34].
Ampicillin (Amp) and ciprofloxacin (CIP) (Sigma-Aldrich, St. Louis, MO, USA) were used as standards.
Prior to testing, each strain was passaged onto nutrient agar (Oxoid, Basingstoke, UK) with 5% of
bovine blood, and bacterial inocula were prepared by suspending a small portion of the bacterial colony
in sterile phosphate-buffered saline (pH 7.2–7.3). The cell density was adjusted to 0.5 McFarland units
using a densitometer (Densi-La-Meter, LIAP, Riga, Latvia). This inoculum was diluted to reach the final
concentration of bacterial cells 5× 105 CFU/mL in the wells. The compounds were dissolved in DMSO
(Sigma-Aldrich, St. Louis, MO, USA), and the final concentration of DMSO in the Cation Adjusted
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Mueller-Hinton (CaMH) broth (Oxoid) for Staphylococci or brain-heart infusion for Enterococci did not
exceed 2.5% of the total solution composition. The final concentrations of the evaluated compounds
ranged from 256 to 0.008 µg/mL. The broth dilution micro-method, modified according to NCCLS
(National Committee for Clinical Laboratory Standards) guidelines [35] in MH broth for Staphylococcus
strains and CaMH for Enterococcus strains, was used to determine MIC. Drug-free controls, sterility
controls, and controls consisting of MH and CaMH broths and DMSO alone were included. The
determination of results was performed visually after 24 h of static incubation in darkness at 37 ◦C in
an aerobic atmosphere.
(b) Other Gram-positive (Streptococcus pneumoniae MFBF 10373, Bacillus cereus ATCC 11778, and
Bacillus subtilis ATCC 6633) and Gram-negative bacteria species (Pseudomonas aeruginosa ATCC 27853,
Escherichia coli ATCC 10536, Serratia marcescens ATCC 10905, Proteus mirabilis MFBF 10430, Acinetobacter
baumannii MFBF 10913, and Salmonella enteritidis MFBF 11945): Serial microdilution broth assay was
used to determine MIC of compounds 4a–f and 5a–f [36]. Cell suspensions were prepared from stock
cultures using phosphate-buffered saline (PBS) (Gibco Laboratories, USA) pH 7.4 and adjusted to
0.5 McFarland units using a nephelometer (ATB 1550, BioMérieux, France). Stock solutions of the
tested compounds were prepared in DMSO (10 mg/mL). Testing was performed using serial dilution
in microtiter flat-bottom 96-well plates with compounds ranging from 100 to 0.78125 µg/mL. After
inoculation (107 CFU/mL) and incubation (18 h, 35 ◦C, aerobically in darkness), MICs for bacterial
species were determined by addition of 0.5 mg/mL TTC (2,3,5-triphenyl-2H-tetrazolium chloride).
The absorbance was recorded at 540 nm. As a positive quality control (susceptibility of strains)
tetracycline hydrochloride (TC) (Sigma-Aldrich) was added into wells. MICs were determined as
non-linear regression using GraphPad Prism as the lowest concentrations resulting in 50% growth
inhibition of growth in comparison to control.
(c) Mycobacteria: Mycobacterium tuberculosis H37Ra ATCC 25177 was grown in Middlebrook broth
(MB), supplemented with Oleic-Albumin-Dextrose-Catalase (OADC) supplement (Difco, Lawrence,
KS, USA) and mycobactin J (2 µg/mL). At log phase growth, a culture sample (10 mL) was centrifuged
at 15,000 rpm/20 min using a bench-top centrifuge (MPW-65R, MPW Med Instruments, Poland).
Following removal of the supernatant, the pellet was washed in fresh Middlebrook 7H9GC broth
and re-suspended in fresh, ODAC-supplemented MB (10 mL). The turbidity was adjusted to match
McFarland standard No. 1 (3 × 108 CFU) with MB broth. A further 1:20 dilution of the culture was
then performed in MB broth. The antimicrobial susceptibility of M. tuberculosis was investigated
in a 96-well plate format. In these experiments, sterile deionised water (300 µl) was added to all
outer-perimeter wells of the plates to minimize evaporation of the medium in the test wells during
incubation. Each evaluated compound (100 µL) was incubated with M. tuberculosis (100 µl). Dilutions
of each compound were prepared in duplicate. For all synthesized compounds, final concentrations
ranged from 1000 µg/mL to 8 µg/mL. All compounds were dissolved in DMSO, and subsequent
dilutions were made in supplemented MB. The plates were sealed with parafilm and incubated at
37 ◦C for 7 days. Following incubation, 10% of alamarBlue (Difco, Lawrence, KS, USA) was mixed
into each well, and readings at 570 nm and 600 nm were taken, initially for background subtraction
and subsequently after 24 h reincubation. The background subtraction is necessary for strongly
coloured compounds, where the colour may interfere with the interpretation of any colour change. For
non-interfering compounds, a blue colour in the well was interpreted as the absence of growth, and a
pink colour was scored as growth.
The evaluation of the in vitro antimycobacterial activity of the compounds was additionally
performed against M. smegmatis ATCC 700084, M. marinum CAMP 5644 and M. kansasii DSM
44162. The broth dilution micro-method in Middlebrook 7H9 medium (Difco, Lawrence, KS, USA)
supplemented with ADC Enrichment (Becton, Dickinson and Comp.) was used to determine MIC as
previously described [37]. The compounds were dissolved in DMSO (Sigma-Aldrich), and the final
concentration of DMSO did not exceed 2.5% of the total solution composition. Final concentrations
of the evaluated compounds ranging from 256 µg/mL to 0.125 µg/mL were obtained by twofold
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serial dilution of the stock solution in a microtiter plate with sterile medium. Bacterial inocula were
prepared by transferring colonies from culture to sterile water. The cell density was adjusted to 0.5
McFarland units using a densitometer (Densi-La-Meter, LIAP, Riga, Latvia). The final inoculum was
made by 1:1000 dilution of the suspension with sterile water. Drug-free controls, sterility controls and
controls consisted of medium and DMSO (Sigma-Aldrich, St. Louis, MO, USA) alone were included.
The determination of results was performed visually after 3 days of static incubation in darkness at
37 ◦C in an aerobic atmosphere for M. smegmatis, after 7 days of static incubation in darkness at 37
◦C in an aerobic atmosphere for M. kansasii and after 21 days of static incubation in darkness at 28 ◦C
in an aerobic atmosphere for M. marinum. Ciprofloxacin (CIP), rifampicin (RIF) and isoniazid (INH)
(Sigma-Aldrich, St. Louis, MO, USA) were used as the standards.
3.2.2. In Vitro Antifungal Susceptibility Testing
Microdilution method was used for testing the antifungal activities of newly synthesized
compounds against Candida albicans CCM 8261 and ATCC 90028, C. krusei CCM 8271, C. parapsilosis
CCM 8260 (Czech Collection of Microorganisms, Brno, Czech Republic) [38]. Tested compounds were
diluted in RPMI-1640 (Sigma) broth to concentrations 128–0.016 µg/mL. Flucytosine (FLU) (Sigma)
and amphotericin B (Amph) were used as positive controls. The plates were inoculated by an inoculum
prepared in RPMI-1640 broth. The final concentration of fungal cells was 5 × 102–2.5 × 103 CFU/mL
in each well. The plates were incubated at 37 ◦C for 24 (C. albicans, C. krusei) or 48 (C. parapsilosis) hours.
Drug-free controls were included. MIC was defined as 80% or greater (IC80) reduction of growth in
comparison with the control [35].
MIC determination for Aspergillus brasiliensis was performed in RPMI 1640 broth with
glutamine supplemented with 2% glucose, following the same scheme as for bacteria, procedure
b). After incubation period (48 h, 35 ◦C, aerobically in dark), XTT (2H-tetrazolium, 2,3-bis(2-methoxy-
4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-hydroxide) (10 mg/mL) in combination with
menadione (1 mg/mL in acetone) (7:1, v/v) was added [36]. Absorbance was read at 540 nm. Amph
was used as a positive control and solvent and media (no microorganisms added) as negative controls.
3.2.3. Minimum Biofilm Eradication Assay
Biofilm eradication screening was performed on the following microorganisms: S. aureus ATCC
6538, S. pneumoniae MFBF 10373, E. faecalis ATCC 29212, B. cereus ATCC 11778, B. subtilis ATCC
6633, E. coli ATCC 10536, P. aeruginosa ATCC 27853, S. marcescens ATCC 10905, P. mirabilis MFBF
10430, S. enteritidis MFBF 11945, A. baumannii MFBF 10913, and C. albicans ATCC 90028. MBECs of
fumardiamides 4a–f and succindiamides 5a–f were determined as follows [39]. Each well (96-well
plate) was filled with 100 µl of bacterial (107 CFU/mL) or yeast (5 × 106 CFU/mL) suspension. When
the inhibition of yeast biofilm formation was tested, the wells were pre-treated with fetal bovine serum
(FBS) (250 µl per well). Negative controls contained broth only. Positive controls were performed using
standard antimicrobial drugs gentamycin (Gen) and Amph, respectively. The plates were covered
and incubated aerobically for 24 h (bacteria) or 48 h (yeast) at 37 ◦C. Following incubation period,
each well was aspirated, washed three times and vigorously shaken to remove all non-adherent
bacteria/yeast. The remaining attached cells were fixed with methanol (15 min) and the plates were
left to dry overnight. Formed biofilm was stained with crystal violet (1%, 5 min). Excess stain was
rinsed by placing the plate under running tap water and the plates were left to dry. Adherent cells
were solubilized using ethanol. The absorbance was read at 570 nm. The MBEC value represents the
lowest dilution of a compound at which bacteria fail to grow.
3.2.4. Antiviral Evaluation
Antiviral activity of compounds 4a–f and 5a–f was determined as described previously [40].
Cytotoxicity and antiviral activity assay towards herpes simplex virus (HSV) strains HSV-1 KOS,
HSV-2 G, HSV-1 TK-KOS ACVr, vaccinia virus, adenovirus-2, human coronavirus (229E) in HEL
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cell cultures, vesicular stomatitis virus, coxsackie virus B4, respiratory syncytial virus in Hela
cell cultures, para-influenza-3 virus, reovirus-1, sindbis, coxsackie virus B4, Punta Toro virus,
yellow fever virus in Vero cell cultures, while influenza A/H1N1 A/Ned/378/05, influenza
A/H3N2 A/HK/7/87 and influenza B B/Ned/537/05 viruses in Madin-Darby Canine Kidney
(MDCK) cell cultures were performed. On the day of the infection, growth medium was aspirated
and replaced by serial dilutions of the test compounds. Virus was then added to each well,
diluted to obtain a viral input of 100 CCID50 (CCID50 being the virus dose that is able to
infect 50% of the cell cultures). Mock-treated cell cultures receiving solely the test compounds
were included, to determine their cellular cytotoxicity. After 3 to 10 days of incubation the
virus-induced cytopathicity was determined by visual scoring of the cytopathic effect (CPE)
(light microscopic evaluation of the virus-induced CPE and inhibition of evaluated compounds),
as well as by measuring the cell viability with the colorimetric formazan-based MTS assay
(3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). All
experiments were performed in duplicate. Antiviral activity was expressed as EC50. The activities were
compared with the activities of the parent drug PQ, DS-10.000 (dextran sulfate, approx. MW = 10.000)
and standard antiviral drugs: ribavirin (Rib), mycophenolic acid (MPA), brivudin, cidofovir, acyclovir,
gancyclovir, zalcitabine, alovudine, UDA, zanamivir, amantadine and rimantadine.
3.2.5. Cytostatic Activity
Cytostatic activity was evaluated in vitro on nine different types of human tumor cell lines:
Capan-1, Hap1, HCT-116, and NCI-H460, as well as hematological tumors such as DND-41, HL-60,
K-562, MM.1S and Z-138 as described previously [41]. All human tumor cell lines were acquired from
the American Type Culture Collection (ATCC, Manassas, VA, USA), except for the DND-41 cell line
which was purchased from the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ
Leibniz-Institut, Braunschweig, Germany) and the Hap1 cell line which was purchased from Horizon
Discovery (Waterbeach, UK). Capan-1, Hap1, HL-60, K-562, Z-138, MM.1S and DND-41 were cultured
in Iscove′s Modified Dulbecco′s Medium (IMDM, Gibco Life Technologies, Gaithersburg, MD, USA),
HCT-116 were grown in McCoy′s 5A Medium (Gibco Life Technologies) and NCI-H460 were cultured
in RPMI (Gibco Life Technologies). All media were supplemented with 10% FBS (HyClone, GE
Healthcare Life Sciences, USA). Adherent cell lines HCT-116, Hap1, NCI-H460, and Capan-1 cells were
seeded at a density between 400 and 1250 cells per well, in 384-well, black-walled, clear-bottomed tissue
culture plates (Greiner Bio-One, Kremsmünster, Germany). After overnight incubation, cells were
treated with test compounds at four different concentrations ranging from 100 to 0.8 µM. Suspension
cell lines HL-60, K-562, Z-138, MM.1S, and DND-41 were seeded at densities ranging from 3000 to
10,000 cells per well in 384-well, black-walled, clear-bottomed tissue culture plates containing test
compounds at the same four concentrations. The plates were incubated and monitored at 37 ◦C for
72 h in an IncuCyte (Essen BioScience Inc., Ann Arbor, MI, USA) for real-time imaging. Images were
taken every 3 h, with one field image per well under 10×magnification. All compounds were tested
with duplicate data points and averaged. The activities were compared with the activities of the parent
drug PQ and standard anticancer drugs docetaxel (DXT), etoposide (EPEG) and staurosporine (STS).
3.2.6. Interaction with Glutathione (GSH)
Fumardiamide 4b (1.25 µM) was incubated with GSH (125 µM) in ammonium formate buffer
(pH = 7.4) containing 10% acetonitrile at 37 ◦C for 216 h [33]. The progress of the reactions was
monitored with the percent of remaining fumardiamide determined by MS using an internal standard
(N-(benzyloxy)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}butanediamide). Aliquots of the reaction
mixture (taken after 0, 4.5, 26, 52, 124 and 216 h) were analysed with Synapt G2-Si ESI-QTOF-MS
system (Waters, Milford, USA). The aliquots were diluted 10 times with acetonitrile and sprayed
at a flow rate of 50µL/min using the fluidics system of the instrument. MS conditions were set as
follows: positive ion mode, capillary voltage 3 kV, sampling cone voltage 10 V, source temperature
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120 ◦C, desolvation temperature 350 ◦C, desolvation gas flow 800 L/h. Mass spectra were recorded
from 100–1000 m/z at a frequency of 1 Hz. Data were acquired and analysed with Waters MassLynx
v4.1 software.
4. Conclusions
Twelve novel PQ-derivatives of diamide type were designed and synthesized. These compounds
differ in the type of spacer and/or halogen atom in aniline region. Compounds 4a–f are fumardiamides
and 5a–f succindiamides. Compounds 4a,b, 5a,b are fluoro, 4c,d, 5c,d chloro and 4e,f, 5e,f are
trifluoroderivatives. All new compounds were screened for antibacterial, antitubercular, antiviral and
cytostatic activity as well as biofilm eradication ability. In all biological assays, fumardiamides
4 were superior to succindiamides 5, which indicates that the double bond conjugated to the
carbonyl was important for the activity. With their high bioactivity, low cytotoxicity and convenient
drug-like properties, p-substituted derivatives 4b,d,f provide a strong basis for further research and
optimization of novel agents useful in the treatment of bacterial and biofilm-associated infections,
while m-substituted derivatives 4a,c,e could be potential leads for the development of antitumor agents.
Supplementary Materials: The following are available online: Table S1. Properties of novel compounds calculated
with Chemicalize.org program. The Lipinski and Gelovani parameters; Table S2. Analytical and spectral
data of compounds 4a–f and 5a–f; Table S3. 1H and 13C NMR spectra of amides 4a–f and 5a–f; Table S4.
Interaction of fumardiamide 4b with GSH; Figure S1. Interaction of fumardiamide 4b with GSH (). Control:
(N-(benzyloxy)-N′-{4-[(6-methoxyquinolin-8-yl)amino]pentyl}butanediamide) (•). Spectra of all compounds.
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